Abbott Laboratories $ABT Shares Bought by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of Abbott Laboratories (NYSE:ABT) by 11.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 975,819 shares of the healthcare product maker’s stock after buying an additional 100,479 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Abbott Laboratories were worth $100,187,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ABT. Renaissance Technologies LLC increased its position in Abbott Laboratories by 122.0% in the 1st quarter. Renaissance Technologies LLC now owns 1,238,666 shares of the healthcare product maker’s stock valued at $127,174,000 after acquiring an additional 680,600 shares during the period. Bollard Group LLC boosted its position in Abbott Laboratories by 16.3% during the 1st quarter. Bollard Group LLC now owns 79,773 shares of the healthcare product maker’s stock worth $8,191,000 after acquiring an additional 11,206 shares during the period. Gamco Investors INC. ET AL grew its stake in shares of Abbott Laboratories by 1.2% in the first quarter. Gamco Investors INC. ET AL now owns 22,568 shares of the healthcare product maker’s stock worth $2,317,000 after purchasing an additional 260 shares in the last quarter. Hilltop Holdings Inc. increased its holdings in shares of Abbott Laboratories by 226.8% during the first quarter. Hilltop Holdings Inc. now owns 9,681 shares of the healthcare product maker’s stock valued at $994,000 after purchasing an additional 6,719 shares during the period. Finally, Orleans Capital Management Corp LA raised its stake in shares of Abbott Laboratories by 2.2% during the first quarter. Orleans Capital Management Corp LA now owns 15,941 shares of the healthcare product maker’s stock valued at $1,637,000 after purchasing an additional 340 shares in the last quarter. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $103.13 on Friday. The company has a 50-day moving average of $91.61 and a 200-day moving average of $101.33. The firm has a market cap of $179.63 billion, a price-to-earnings ratio of 33.38, a price-to-earnings-growth ratio of 1.95 and a beta of 0.61. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The business had revenue of $12.51 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same period in the previous year, the firm earned $1.26 EPS. The business’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts forecast that Abbott Laboratories will post 5.51 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is 81.55%.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Evercore dropped their price target on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. JPMorgan Chase & Co. raised their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Sanford C. Bernstein dropped their target price on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. TD Cowen restated a “buy” rating and issued a $115.00 target price on shares of Abbott Laboratories in a research report on Friday, July 17th. Finally, Wells Fargo & Company lifted their price target on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.61.

Insider Buying and Selling at Abbott Laboratories

In related news, Director Daniel J. Starks acquired 10,000 shares of Abbott Laboratories stock in a transaction dated Monday, April 27th. The stock was acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.